Your browser is no longer supported. Please, upgrade your browser.
Settings
SBPH Spring Bank Pharmaceuticals, Inc. daily Stock Chart
SBPH [NASD]
Spring Bank Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.37 Insider Own4.00% Shs Outstand16.47M Perf Week-1.37%
Market Cap165.69M Forward P/E- EPS next Y-2.45 Insider Trans- Shs Float14.03M Perf Month0.50%
Income-18.90M PEG- EPS next Q-0.65 Inst Own42.90% Short Float1.86% Perf Quarter-12.22%
Sales- P/S- EPS this Y-3.70% Inst Trans58.86% Short Ratio4.93 Perf Half Y-28.09%
Book/sh4.08 P/B2.47 EPS next Y-35.40% ROA-34.40% Target Price30.40 Perf Year-16.79%
Cash/sh3.25 P/C3.10 EPS next 5Y- ROE-47.40% 52W Range8.88 - 15.95 Perf YTD-25.15%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-36.93% Beta-
Dividend %- Quick Ratio10.70 Sales past 5Y- Gross Margin- 52W Low13.29% ATR0.57
Employees21 Current Ratio10.70 Sales Q/Q- Oper. Margin- RSI (14)35.93 Volatility2.84% 5.34%
OptionableNo Debt/Eq0.00 EPS Q/Q30.60% Profit Margin- Rel Volume1.14 Prev Close10.02
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume52.96K Price10.06
Recom1.70 SMA20-8.34% SMA50-13.03% SMA200-22.42% Volume60,633 Change0.40%
Oct-09-18Initiated Jefferies Buy
Feb-21-18Reiterated Cantor Fitzgerald Overweight $29 → $32
Nov-06-17Initiated B. Riley FBR, Inc. Buy $30
Aug-01-17Reiterated Chardan Capital Markets Buy $34 → $30
Jul-20-17Initiated Cantor Fitzgerald Overweight $29
May-24-17Reiterated Chardan Capital Markets Buy $16.50 → $34
May-19-17Initiated JMP Securities Mkt Outperform $20
May-02-17Initiated Chardan Capital Markets Buy $16.50
Dec-06-18 07:00AM  Spring Bank Pharmaceuticals Hosts R&D Day on Pipeline of Novel Immunomodulatory Therapeutics GlobeNewswire
Nov-29-18 08:00AM  Spring Bank Announces Additional Pre-Clinical Data on Its Second-Generation STING Agonist Program at the AACR Special Conference on Tumor Immunology and Immunotherapy GlobeNewswire
Nov-09-18 08:00AM  Spring Bank Announces Additional Inarigivir Results at AASLD Conference GlobeNewswire -5.09%
Nov-05-18 08:00AM  Spring Bank Pharmaceuticals, Inc. to Present at Upcoming Healthcare Conferences GlobeNewswire +8.24%
Nov-01-18 08:00AM  Spring Bank Announces Three Poster Presentations on Its Next-Generation STING Agonist Program at the AACR Special Conference on Tumor Immunology and Immunotherapy GlobeNewswire -5.17%
Oct-29-18 11:00AM  Spring Bank Pharmaceuticals to Host R&D Day on Thursday, December 6, 2018 GlobeNewswire
Oct-25-18 04:30PM  Spring Bank Pharmaceuticals Reports Third Quarter Financial Results GlobeNewswire -5.41%
Oct-03-18 05:02PM  Spring Bank Announces Inarigivir Data Presentations at AASLD Conference GlobeNewswire
Sep-17-18 08:00AM  Spring Bank Pharmaceuticals, Inc. to Present at the 2018 Cantor Global Healthcare Conference GlobeNewswire -5.68%
Aug-16-18 08:00AM  Spring Bank Pharmaceuticals, Inc. Appoints Scott Smith to its Board of Directors GlobeNewswire
Aug-13-18 09:55PM  Edited Transcript of SBPH earnings conference call or presentation 2-Aug-18 12:00pm GMT Thomson Reuters StreetEvents
Aug-08-18 09:33PM  Spring Bank Announces Pricing of Public Offering of Common Stock GlobeNewswire
04:01PM  Spring Bank Announces Proposed Public Offering of Common Stock GlobeNewswire
Aug-02-18 06:00AM  Spring Bank Announces Positive Study Results from the Inarigivir ACHIEVE Trial GlobeNewswire +11.16%
Aug-01-18 04:01PM  Spring Bank Pharmaceuticals Reports Second Quarter Financial Results GlobeNewswire
May-29-18 08:30AM  Spring Bank to Present at Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-03-18 07:10AM  Wired News Ophthotech Announced Completion of Patient Enrollment in Phase-2a Clinical Trial of Zimura(R) in Wet Age-Related Macular Degeneration ACCESSWIRE
Apr-27-18 08:00AM  Spring Bank Pharmaceuticals Provides Corporate Update and Reports First Quarter Financial and Operational Results GlobeNewswire
Apr-10-18 08:30AM  Spring Bank Announces Expanded Inarigivir Data from the ACHIEVE Trial to Be Presented at The International Liver Congress GlobeNewswire
Mar-14-18 08:00AM  Spring Bank Announces Presentation of Combined Inarigivir 25 mg and 50 mg 12 and 24 Week ACHIEVE Results Demonstrating Enhanced Anti-Viral Efficacy in HBeAg-Negative Patients GlobeNewswire
Mar-11-18 07:05PM  Edited Transcript of SBPH earnings conference call or presentation 21-Feb-18 1:30pm GMT Thomson Reuters StreetEvents
Mar-09-18 02:19PM  Spring Bank to Present at Cowen & Company 38th Annual Health Care Conference GlobeNewswire
Mar-05-18 04:01PM  Spring Bank Pharmaceuticals Appoints Timothy Clackson, Ph.D., to its Board of Directors GlobeNewswire +10.84%
Feb-21-18 06:40AM  Spring Bank Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-20-18 04:30PM  Spring Bank Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial and Operational Results GlobeNewswire
Feb-12-18 08:00AM  Spring Bank to Host Conference Call to Discuss Fourth Quarter and Fiscal Year 2017 Results on Wednesday, February 21 GlobeNewswire
Jan-09-18 08:30AM  Spring Bank Strengthens Management Team to Enhance Operations GlobeNewswire
Nov-15-17 04:30PM  Spring Bank Pharmaceuticals Announces Positive Top-Line Results from the Second Cohort of Part A of the Phase 2 ACHIEVE Trial GlobeNewswire
Nov-07-17 08:00AM  Spring Bank to Present at Piper Jaffrays 29th Annual Healthcare Conference GlobeNewswire
Oct-31-17 06:45AM  Spring Bank Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial and Operational Results GlobeNewswire
Oct-20-17 08:00AM  Spring Bank Pharmaceuticals Announces Additional Inarigivir (formerly SB 9200) Results from the ACHIEVE Trial in HBV Patients at AASLD Conference GlobeNewswire -5.04%
Oct-06-17 08:30AM  Spring Bank Pharmaceuticals Announces Two Presentations at the 2017 AASLD Conference in Washington, D.C. GlobeNewswire +7.76%
Oct-02-17 08:30AM  Spring Bank Pharmaceuticals Announces Presentation of Positive Preclinical Data on SB 11285 at the 2017 AACR Conference on Tumor Immunology and Immunotherapy GlobeNewswire -9.14%
Sep-19-17 08:00AM  Spring Bank Pharmaceuticals Announces a Poster Presentation of its lead STING Agonist, SB 11285, at the 2017 AACR Conference on Tumor Immunology and Immunotherapy in Boston, MA GlobeNewswire
Sep-13-17 08:00AM  Spring Bank to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire +6.02%
Aug-28-17 08:30AM  Spring Bank to Present Additional Data from the First Cohort of its Ongoing SB 9200 ACHIEVE Clinical Trial at the 2017 International HBV Meeting in Washington D.C. GlobeNewswire +8.29%
Jul-31-17 04:15PM  Spring Bank Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2017 Financial and Operational Results GlobeNewswire
Jul-10-17 08:30AM  Spring Bank Announces Collaboration with Gilead for Hepatitis B (HBV) Phase 2 Study Exploring Combination Treatment of SB 9200 and Vemlidy® GlobeNewswire
Jun-22-17 09:00AM  Spring Bank Pharmaceuticals Prices $37.5 Million Public Offering of Common Stock GlobeNewswire -5.52%
Jun-21-17 04:00PM  Spring Bank Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire
Jun-07-17 07:00AM  Spring Bank Provides Update on its Next-Generation STING Platform and Announces Publication of an Abstract at ASCO Related to its Lead STING Agonist Candidate, SB 11285 GlobeNewswire
May-23-17 04:00PM  Spring Bank Pharmaceuticals Announces Top-Line Results from the Initial Cohort of the Phase 2a Segment of the ACHIEVE Trial, a Global Phase 2 Clinical Trial for Chronic Hepatitis B Virus (HBV) GlobeNewswire
May-22-17 04:00PM  Spring Bank Pharmaceuticals to Host Conference Call to Discuss Top-Line Results from the Initial Cohort of the Phase 2a Segment of its ACHIEVE Trial GlobeNewswire
May-15-17 08:00AM  Spring Bank Pharmaceuticals Announces the Data Safety Monitoring Board Approves Dose Escalation of SB 9200 for the Second Cohort of the Phase 2a Segment of the ACHIEVE Trial, a Global Phase 2 Clinical Trial for Chronic Hepatitis B Virus (HBV) GlobeNewswire
May-01-17 08:00AM  Spring Bank Pharmaceuticals to Present at the East Coast IDEAS Investor Conference on May 18th in Boston GlobeNewswire
Apr-28-17 08:30AM  Spring Bank Pharmaceuticals Provides Corporate Update and Reports First Quarter 2017 Financial and Operational Results GlobeNewswire
Apr-21-17 03:05PM  ETFs with exposure to Spring Bank Pharmaceuticals, Inc. : April 21, 2017 Capital Cube
Mar-14-17 02:29PM  Spring Bank Pharmaceuticals, Inc. :SBPH-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Capital Cube
02:29PM  Spring Bank Pharmaceuticals, Inc. :SBPH-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
Feb-27-17 10:00AM  SBPH: 2016 Results Sustaining Continued HBV/STING Development Zacks Small Cap Research +9.44%
Feb-21-17 08:00AM  Spring Bank Pharmaceuticals to Present Results from In Vivo Studies of SB 11285, a Novel STING agonist for Immuno-Oncology, at Keystone Symposia GlobeNewswire
Feb-18-17 01:04PM  SPRING BANK PHARMACEUTICALS, INC. Financials
Feb-15-17 08:00AM  Spring Bank Pharmaceuticals Provides Corporate Update and Reports 2016 Financial and Operational Results GlobeNewswire
Feb-14-17 06:28PM  SPRING BANK PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
Feb-07-17 07:30AM  Spring Bank Pharmaceuticals to Present at the 2nd Annual Disruptive Growth & Healthcare Conference in NYC on February 16 Accesswire -6.34%
Feb-06-17 10:11AM  Spring Bank Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference in NYC GlobeNewswire
Jan-04-17 09:00AM  Garrett Winslow Joins Spring Bank as Vice President of Legal GlobeNewswire
Dec-28-16 02:33PM  Spring Bank Pharmaceuticals Inc (SBPH) An Ace Up Gilead Sciences, Inc. (GILD)s Sleeve Insider Monkey
02:33PM  Spring Bank Pharmaceuticals Inc (SBPH) An Ace Up Gilead Sciences, Inc. (GILD)s Sleeve at Insider Monkey
Dec-23-16 02:00PM  Spring Bank (SBPH) Inks 3rd Collaboration Agreement Zacks Small Cap Research
Nov-03-16 10:00AM  SBPH: Third Quarter has a Sting to it Zacks Small Cap Research
Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using small molecule nucleic acid hybrid (SMNH) chemistry platform. The company's lead SMNH product candidate is inarigivir soproxil, for the treatment of chronic hepatitis B virus (HBV). It is also developing SMNH product candidates, including STimulator of INterferon Genes agonist, an immunotherapeutic agent for the potential treatment of selected cancers. Spring Bank Pharmaceuticals, Inc. has strategic collaborations with Gilead Sciences, Inc. to conduct a Phase II trial examining the co-administration of inarigivir and tenofovir alafenamide in patients infected with HBV. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.